Vinblastine

Generic Name: Vinblastine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₈N_₄O_₉

CAS Number: 865-21-4

Unique Ingredient Identifier: 5V9KLZ54CY

Background: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Indication: For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Associated Conditions: Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer

Associated Therapies: -

Clinical Trials

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

Phase 2

Not yet recruiting

Conditions: Advanced Hodgkin Lymphoma
Classic Hodgkin Lymphoma
Lugano Classification Stage III Hodgkin Lymphoma AJCC v8
Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Dacarbazine
Drug: Doxorubicin
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Biological: Nivolumab
Procedure: Positron Emission Tomography
Drug: Vinblastine
Other: Questionnaire

First Posted Date: 2024-12-20

Last Posted Date: 2024-12-20

Lead Sponsor: University of Washington

Target Recruit Count: 125

Registration Number: NCT06745076

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Brentuximab vedotin
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Vinorelbine
Diagnostic Test: FDG-PET/CT scan

First Posted Date: 2024-04-22

Last Posted Date: 2024-12-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 71

Registration Number: NCT06377566

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States

and more 5 locations

Drug Screening Using IMD in Bladder Cancer

First Posted Date: 2024-01-12

Last Posted Date: 2024-01-12

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 18

Registration Number: NCT06204614

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Classic Hodgkin Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Dacarbazine
Drug: Doxorubicin
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Drug: Vinblastine

First Posted Date: 2023-12-11

Last Posted Date: 2024-03-08

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT06164275

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Cadence Health - CDH, Warrenville, Illinois, United States

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Phase 2

Recruiting

Conditions: Classical Hodgkin Lymphoma

Interventions: Drug: Pembrolizumab
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Brentuximab vedotin

First Posted Date: 2022-06-03

Last Posted Date: 2024-07-03

Lead Sponsor: University of Virginia

Target Recruit Count: 44

Registration Number: NCT05404945

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

Phase 2

Recruiting

Conditions: Grade 1 Glioma
Mixed Glio-neuronal Tumors
Pleomorphic Xanthoastrocytoma

Interventions: Drug: Vinblastine
Drug: Trametinib

First Posted Date: 2022-01-06

Last Posted Date: 2024-08-29

Lead Sponsor: University Hospital, Strasbourg, France

Target Recruit Count: 134

Registration Number: NCT05180825

Locations: 🇫🇷
Chu de Besancon, Besancon, France
🇫🇷
CHU de REIMS, Reims, France
🇫🇷
Groupe Hospitalier Pellegrin, Bordeaux, France

and more 22 locations

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2

Recruiting

Conditions: Urothelial Carcinoma
Bladder Cancer

Interventions: Other: Abiraterone acetate
Drug: Durvalumab
Drug: Methotrexate
Drug: Vinblastine
Drug: Doxorubicin Hydrochloride
Drug: Cisplatin

First Posted Date: 2021-11-30

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05137262

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis

Phase 2

Recruiting

Conditions: AML
Hyperleukocytosis

Interventions: Drug: Hydroxyurea capsules
Drug: Vinblastine

First Posted Date: 2021-09-30

Last Posted Date: 2021-10-18

Lead Sponsor: Hospital Universitario Dr. Jose E. Gonzalez

Target Recruit Count: 46

Registration Number: NCT05062278

Locations: 🇲🇽
Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer, Monterrey, Nuevo Leon, Mexico

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Phase 2

Completed

Conditions: Classical Hodgkin Lymphoma

Interventions: Biological: Pembrolizumab
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Bleomycin
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Procarbazine
Drug: Prednisone

First Posted Date: 2021-08-17

Last Posted Date: 2024-11-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 146

Registration Number: NCT05008224

Locations: 🇺🇸
Stanford Cancer Center ( Site 0023), Palo Alto, California, United States
🇺🇸
Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
🇺🇸
Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States

and more 45 locations

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Phase 3

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Radiation: Involved site radiotherapy
Drug: Doxorubicin
Drug: Bleomycin
Drug: Brentuximab vedotin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Haematopoietic growth factor

First Posted Date: 2020-12-28

Last Posted Date: 2024-10-30

Lead Sponsor: University College, London

Target Recruit Count: 1042

Registration Number: NCT04685616

Locations: 🇳🇱
Reinier de Graafweg 3-11 - Postbus 5011 - 2625 AD Delft, Delft, Netherlands
🇬🇧
Colchester Hospital, ESNEFT, Colchester, United Kingdom
🇬🇧
The Clatterbridge Cancer Centre NHSFT, 65 Pembroke Place, Liverpool, United Kingdom

and more 38 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy